CARTHERICS TO PRESENT AT THE 2025 BIO INTERNATIONAL CONVENTION

• Cartherics' Chief Operating Officer, Dr. Ian Nisbet, will be presenting at BIO on Monday 16th June, 2025 at 1.30pm (US EDT).

Melbourne, Australia, 28 May 2025 - Cartherics Pty Ltd ("Cartherics" or "Company"), a biotechnology company focused on developing immune cell therapies for cancer and other diseases, announced today that Dr. Ian Nisbet, COO, will present at the upcoming 2025 BIO International Convention June 16-19 2025, in Boston Massachusetts.

Dr Nisbet's presentation, titled, 'Cartherics - Revolutionizing Cellular Therapies for Cancer and Beyond' will take place on Monday 16th June, 2025 at 1.30pm in Room 153C and will discuss the company's pipeline, R&D activities, business objectives and investment goals.

The annual BIO International Convention is the world's largest industry gathering. It provides a unique opportunity to engage with senior biotech executives, business development leaders and investors. BIO is an ideal setting for Cartherics to showcase its innovative cell therapy platform targeting ovarian cancer, endometriosis, and other indications.

Cartherics' proprietary platform leverages induced pluripotent stem cells (iPSC) to generate homogenous, natural killer (NK) cells using a scalable manufacturing process. The NK cells engineered to carry chimeric antigen receptors (CARs) for precision targeting of solid tumors and, potentially, endometriosis. The pipeline includes multiple assets with dual-targeting and immune evasion resistance, covered by strong patent protection.

CTH-401, Cartherics' lead cell therapy candidate, is the only NK cell product in development that features a CAR targeting TAG-72, a well-established tumor marker broadly expressed across multiple adenocarcinomas, including ovarian, gastric, colorectal, prostate, and pancreatic cancers.

Cartherics has shown that CTH-401 is highly effective at eliminating ovarian cancer cells in both tissue culture and animal models, with regulatory approval for the first clinical trial targeted for next year. As demand grows for scalable allogeneic therapies, pharma partners and investors are prioritising near-term, de-risked innovations like this more than ever.

Dr. Nisbet commented: "Cartherics has established a powerful platform for generating an effectively unlimited supply of CAR-NK cells that are potential therapies for poorly treated and underserved diseases like cancer and endometriosis. BIO presents a fantastic opportunity to showcase this platform to the world."

Cartherics acknowledges and thanks the Victorian government, Austrade and MTPConnect for financial and organisational support to attend BIO.
******

12 Ferntree Place
Notting Hill
Victoria, Australia 3168

Media contact
Christine Filippis
Teraze Communications
Phone: +61 419 119 866
Email: christine@teraze.com.au

About Cartherics
Cartherics Pty Ltd is a privately held biotechnology company based in Melbourne, Australia that is rearming the body's immune system to fight cancer, endometriosis and potentially Alzheimer's Disease. It is developing cell-based immunotherapies for the treatment of cancer and endometriosis, with a portfolio of CAR-T and CAR-NK cell products. The Company's allogeneic ("off-the-shelf") cell platform is based upon induced pluripotent stem cells (iPSCs) generated from donated cord blood that can be differentiated into NK cells, T cells and other cells of the immune system. The iPSCs are genetically engineered at specific "safe harbour" genomic sites to provide enhanced function for the derived NK and other immune cells. The Company's lead product, CTH-401, is a CAR-iNK cell product. It carries a CAR directed against TAG-72, a well-validated tumour target, along with the deletion of two genes associated with immunosuppression. The company has a strong pipeline of CAR-immune cell products tailored to disrupt ovarian cancer and endometriosis.
https://cartherics.com/
Watch our latest company video here: https://www.youtube.com/watch?v=rxQEyx6i7hk

This release was published on openPR.